Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 7/20 | 0.48 |
| ▸ | SUCNR1 | Q9BXA5 | 7/20 | 0.48 |
| ▸ | F11 | P03951 | 2/20 | 0.48 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410450 | 1.00 | CFD (0.48) | CFDSUCNR1F11TPSB2SMN1; SMN2 | |
| SCHEMBL16403613 | 0.91 | CFD (0.61) | CFDSUCNR1F11TPSB2SMN1; SMN2 | |
| SCHEMBL16403586 | 0.91 | CFD (0.61) | CFDSUCNR1F11TPSB2SMN1; SMN2 | |
| SCHEMBL17772668 | 0.90 | SMN1; SMN2 (0.43) | CFDSMN1; SMN2MAPTRAB9AROCK2 | |
| SCHEMBL17764302 | 0.87 | SUCNR1 (0.43) | SUCNR1SMN1; SMN2MAPTRAB9ALMNA | |
| SCHEMBL17802755 | 0.85 | SUCNR1 (0.51) | CFDSUCNR1F11TPSB2SMN1; SMN2 | |
| SCHEMBL17764307 | 0.85 | CFD (0.49) | CFDSUCNR1F11TPSB2SMN1; SMN2 | |
| SCHEMBL17764531 | 0.85 | CFD (0.49) | CFDSUCNR1F11TPSB2SMN1; SMN2 | |
| SCHEMBL16410291 | 0.85 | CFD (0.49) | CFDSUCNR1F11TPSB2SMN1; SMN2 | |
| SCHEMBL16403609 | 0.82 | SUCNR1 (0.56) | CFDSUCNR1F11TPSB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CFD 1/4885SUCNR1 4670/4885F11 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.